



The growing family of targeted therapies for inflammatory skin disease 
 
Authors: Schlapbach C (MD PhD), Navarini AA (MD PhD) 
 
Financial disclosure: 
Relationships relevant to this manuscript:.  
None of the authors have relevant financial relationships to this manuscript.  
 
Word count: 4500 words 
 
Abstract 
Treatment of inflammatory skin disease has evolved from broad suppression of immune cells 
to increasingly specific targeting and modulation of immune mechanisms at all levels. This 
has led to dramatic treatment successes as well as a better understanding of the 
pathophysiology. The cycle of in vitro studies, animal models, case series and clinical trials 
forms a feedback loop that informs and guides the design of ever better disease models and 
therapeutic targets. Not only have we identified new cytokines driving skin inflammation, we 
have also found that psoriasis and other autoimmune conditions are driven by distinct 
mediators occurring in early and late phases, which could be an opportunity for phase-
specific or multi-pronged interventions. The deeper our mechanistic understanding, the more 
likely we will be to discover subtle strategies to reprogram each patients’ immune cells 
without having to dampen or eliminate their protective effects against pathogens and tumors. 
Lastly, ongoing genomic studies might soon confirm interesting genetic markers for 
predictive personalized medicine in psoriasis such as HLA-Cw6 and TNFAIP3.  Taken 
together, the growing family of immune therapies in skin will potentially allow an 
unprecedented form of medicine that is not bent on destroying the pathogenic mechanism, 
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Thanks to novel insights into the genetic and immunological background of inflammatory skin 
disease we have today a better understanding of the complex molecular and cellular events 
that initiate and maintain inflammation in cutaneous pathology. These novel disease models 
have driven the development of targeted therapies with unprecedented clinical efficacy. In 
turn, feedback from translational and clinical studies of patients treated with targeted 
therapies is utilized to guide the refinement and validation of these disease models (Fig. 1)1. 
 
Good examples for this mechanism are the discovery of the role of TNF in psoriasis by initial 
chance observations and subsequent clinical trials, which improved our understanding of 
psoriasis models enormously. 
In this article, we will first discuss the growing family of targeted therapies under the 
viewpoint of emerging models of inflammatory skin disease, namely the dichotomous models 
of triggering vs. maintenance and suppression vs. deviation of immune responses, and 
evaluate conclusions that can be drawn from observing clinical outcomes in patients under 
this view. Then, we will evaluate the hidden potential of synergic therapy, where two or more 
targets with known synergic pathogenetic effects are targeted simultaneously to achieve a 
greater therapeutic effect. Finally, we aim at elucidating the advantages and disadvantages 
of large-scale clinical trials versus careful, detailed observations of small cohorts of patients 
treated with targeted therapies through the eyes of physicians and scientist with a profound 
understanding of the underlying pathomechanism. 
 
Targeted therapies for early and chronic cutaneous inflammation 
Most inflammatory skin diseases are chronic in nature, but the clinical course can range from 
relatively stable diseases such as stable plaque-type psoriasis to chronic-relapsing diseases 
with sudden exacerbations such as pustular psoriasis or atopic dermatitis.2,3 Triggers that 
initiate stable disease or exacerbate relapsing disease may be of exogenous or endogenous 
nature and provoke early inflammatory events that are distinct from the ones in late 
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inflammation responsible for stable disease.4 Indeed, sterile inflammation in the initiation 
phase of inflammatory skin disease is mediated by the innate immune system and can thus 
be classified as autoinflammatory.4,5 Autoinflammation is driven by endogenous danger 
signals, metabolic mediators as well as cells and cytokines of the innate immune system 
such as IL-1, IL-8, and TNF-α. Late inflammation, on the other hand, is considered to be 
driven and maintained, respectively, by activated cells of the adaptive immune cells, mainly T 
cells in the case of cutaneous inflammation.1 Therefore, cutaneous inflammation in skin 
disease can be viewed as consisting of two phases of overarching but distinct types of 
inflammation: (1) An autoinflammatory phase, driven by endogenous or exogenous triggers, 
mediated by the innate immune system, and implicated in initiating disease and (2) an 
autoimmune phase, which is initiated by these autoinflammatory events but mediated by the 
adaptive immune system. The autoimmune phase is considered to play the predominant role 
in chronic stable disease.4 
 
A typical example of such interplay between autoinflammatory and autoimmune inflammation 
in skin disease can be observed in plaque type psoriasis. According to the model of biphasic 
immune activation, psoriasis lesions are initiated by repeated bursts of innate inflammation, 
consisting of toll-like receptor activated dendritic cells, rapid release of cytokines of the IL-1 
family and recruitment of neutrophils. In a transitional period, T helper type 17 cells (Th17) 
are attracted and activated by DC-derived IL-23 and, likely together with neutrophils, release 
large amounts of IL-17.1,6 Then, an immunological switch takes place with the dendritic cells 
starting to produce IFN-α. IFN-α antagonizes IL-1 family member cytokines, suppresses the 
Th17 response and initiates a classical Th1 dominated cytokine milieu with the influx of IFN-γ 
producing Th1 cells and macrophages, thus heralding the beginning of the chronic stable 
stage of inflammation.7 In this process, differentiation of Th1 cells is dependent on IL-12 
produced by macrophages and DCs. Taken together, in classical psoriasis plaques, bursts of 
innate autoinflammation coexist with T-cell driven autoimmune inflammation.4 The 
corresponding histopathological features are infiltration of activated innate immune cells such 
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as mast cells and neutrophils in developing psoriatic lesions and a predominance of 
activated T cells and macrophages in stable psoriasis lesions.3,8,9 The corresponding clinical 
features are pustular eruptions for highly acute psoriasis and pitted nails due to recurrent 
neutrophils eruptions in the nail bed as a sign of recurrent local autoinflammation. 
 
A similar dichotomous or biphasic view on the inflammatory process can be applied to atopic 
dermatitis:2 In the initiation phase of allergic skin inflammation, exogenous triggers such as 
allergens (e.g. house dust mites), viruses, and bacteria (e.g. Staph. aureus) induce the 
production of innate cytokines like thymic stromal lymphopoietin (TSLP) and IL-33 from 
keratinocytes which in turn induce secretion of IL-5 and IL-13 from innate lymphoid cells 
(ILCs) and IL-10 from Langerhans cells. This initial innate immune response triggers a mixed 
innate/adaptive transitional phase where Th2 cells are activated to produce more IL-4, IL-13 
and IL-31, B cells undergo isotype class switch to produce IgE antibodies, and eosinophils 
and basophils start to infiltrate the skin. Finally, in the chronic stage of atopic dermatitis, the 
inflammatory picture is dominated by adaptive immunity with Th22 cells and Th1 cells 
producing IL-22 and IFN-γ, respectively. The differentiation and maintenance of these T cell 
subsets are thought be maintained by IL-12 secreting myeloid dendritic cells (mDCs), which 
are also abundantly found in the immune infiltrate of chronic AD.1 
As for psoriasis, these sequential inflammatory processes are also reflected in the 
histopathological and clinical presentation: Histopathology of acute AD shows epidermal 
changes with intercellular edema (spongiosis) and activated LCs and a beginning dermal 
infiltrate consisting of mast cells, T cells and monocytes/macrophages. In chronic lesions, 
macrophages/dendritic cells and T cells dominate the dermal infiltrate, with a few eosinophils 
and non-degranulated mast cells.10 Clinically, early AD lesions are characterized by 
inflammatory papules and vesicles on a background of erythema whereas chronic lesions 
present with infiltrated, fibrotic plaques with scales and lichenification.11 
Taken together, as in psoriasis, the inflammatory processes in AD are characterized by 
distinct but partially overlapping inflammatory phases, namely an early autoinflammatory 
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phase orchestrated by the innate immune system and a chronic autoimmune phase, 
dominated by cells and cytokines of the adaptive immune system. 
 
Today, a plethora of targeted therapies to inhibit multiple of the above mentioned 
inflammatory pathways are either approved or currently in clinical trials (see table X + Y). For 
psoriasis, the approved therapies with long successful clinical track records target TNF-α or 
IL-12/23p40. This group of highly effective biologics was recently joined by monoclonal 
antibodies targeting IL-17 or its receptor, showing impressive therapeutic efficacy. In 
contrast, monoclonal antibodies targeting IL-22 or IFN-γ have shown disappointing results in 
clinical trials in psoriasis, failing to induce major improvements in most patients.1,12 This 
divergent therapeutic efficiency of inhibiting distinct inflammatory pathways now provides the 
basis for validation of established pathogenesis models and reflections on the true 
contributions of these molecules to pathogenesis. For instance, the striking difference in the 
ability to inhibit psoriatic inflammation of anti-IL-17 compared to anti-IFN-γ antibodies, 
despite similar expression levels in situ of these two cytokines,13 raises questions on the 
respective pathogenetic contribution of these two cytokines. A straightforward explanation, of 
course, attributes a lesser pathogenic role to the IL-12/Th1/IFN-γ axis and a central pro-
inflammatory role to the IL-23/Th17/IL-17 axis, thus elegantly explaining the diverging clinical 
efficiency of blocking either pathway. However, given the manifold and well-stablished pro-
inflammatory effects of IFN-γ on immune and non-immune cells,14 many of which have been 
intimately linked to psoriasis pathogenesis,15,16 it appears tempting to also contemplate 
alternative explanations. Similar reflections apply to the cytokine IL-22. Translational 
research has identified IL-22 as a key proinflammatory cytokine in psoriatic skin inflammation 
linking immune and epithelial cells,17 yet antagonism of this cytokine does not improve the 
skin condition of psoriasis patients.1 Again, it can be postulated that IL-22 does therefore not 
play a major pathogenic role, but a more careful look at emerging models of cutaneous 
inflammation might provide new insights. 
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One viewpoint under which these observations can be dissected is the concept of early and 
chronic or autoinflammatory and autoimmune inflammation, as introduced above. Looking at 
the outstanding clinical efficacy of neutralizing TNF-α, IL-12/23p40 or IL-17 and the lack of 
benefit from blocking IFN-g or IL-22, it could also be imagined that, to achieve therapeutic 
effect, it is necessary to inhibit inflammatory signals that act in both the early and the late 
phase of inflammation, or to inhibit signals that play an intricate role in bridging these two 
phases. For example, TNF-α is expressed in the very early phases of innate inflammation by 
stressed keratinocytes but remains a key cytokine in the chronic phase, where it is 
abundantly produced by Th1 cells, macrophages and activated keratinocytes. Thus, 
antagonizing TNF-α will suppress both the early innate and the late adaptive immune 
response, leading to downregulation of initiating as well as maintaining inflammatory signals 
and therefore to successful treatment of psoriasis. Similarly, DC-derived IL-12/23p40 is 
involved in bridging innate and adaptive inflammation, as it is expressed after DCs sense 
innate danger signals and then leads to activation of an adaptive Th1 and Th17 response. 
Therefore, by blocking IL-12/23p40, interference with both the autoimmune and the 
autoinflammatory phase is established and, consequently, successful treatment of psoriatic 
inflammation is observed clinically. These reflections may also apply to the high efficacy of 
neutralizing IL-17 signaling in psoriasis, as IL-17 is increasingly understood to be an intricate 
part of both the early innate and the late adaptive immune response.6,18 
Under the same view, the lack of therapeutic benefit from blocking IFN-y or IL-22 signals in 
psoriasis could be explained by their predominant involvement in late autoimmune but not 
early autoinflammatory phase of inflammation.19 As a consequence, ongoing innate 
stimulation and positive feed-forward loops are not inhibited and continue to trigger adaptive 
inflammation. The concept that abrogation of both phases of inflammation is necessary to 
successfully treat psoriasis is further supported by the conspicuous absence of reports 
showing clinical benefit from blocking early innate mediators such IL-1 (by anakinra, 
canakinumab) or IFN-α, despite available biologicals to neutralize these signals with proven 
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clinical efficacy in inflammatory skin diseases that are characterized by dominating innate 
immune activation such as neutrophil dermatoses and pustular psoriasis.20-22 
 
The same model can be used to analyze efficacy of targeted therapies in atopic dermatitis, 
although clinical experience with these drugs is considerably smaller than in psoriasis and 
clinical trials have just started on a broader scale recently.23 Therefore, only data from clinical 
trials on neutralizing antibodies against IL-5 (mepolizumab)24,25 and IL-4Rα (dupilumab)26,27 
are available as well as a few reports from case series using anti-IL-6R and anti-CD20 
antibodies in atopic dermatitis.28,29 In clinical trials, anti-IL-5 therapy did not show any 
therapeutic effects whereas anti-IL-4Rα treatment, which interferes with both IL-4 and IL-13 
signaling, induced marked and rapid improvement of atopic dermatitis. In the model of early 
and late inflammation, these diverging clinical effects can be explained by the different 
targets of the blocked cytokines. In atopic dermatitis, IL-5 exerts its effects in early 
inflammation, predominantly by promoting accumulation and activation of eosinophils in skin, 
albeit it being expressed by cells of both the innate and adaptive immune system and it 
having effects on isotype class switching in B cells. Thus, neutralization of IL-5 will mainly 
interfere with attraction and activation of eosinophils in early innate inflammation but will fail 
to limit chronic adaptive immune circuits. In contrast, dupilumab blocks the shared alpha 
subunit of the IL-4/IL-13 receptor and thus inhibits proinflammatory signals in all cells that 
express either receptor. These include innate cells such as keratinocytes, dendritic cells, 
innate lymphoid cells as well as adaptive immune cells such as T cells of different subsets 
and B cells. Therefore, blocking the IL-4/IL-13 receptor profoundly dampens innate as well as 
adaptive inflammation in atopic dermatitis and therefore, according to the model of bimodal 
immune activation in cutaneous inflammation, shows great therapeutic effect. This 
hypothesis is further supported in atopic dermatitis by the clinical benefit of interrupting IL-6R 
signaling, as IL-6 is known for its regulatory role in innate and adaptive immunity.29,30 It will be 
highly interesting to see the outcome of ongoing clinical trials in atopic dermatitis with 
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targeted therapeutics against mediators of innate inflammation (IL-33, TSLP) and mixed 
innate/adaptive inflammation (IL-31, IL-22).  
Another cytokines that merits attention along these lines is IL-9. Although discovered 20 
years ago, it remains one of the more enigmatic cytokines so far and its cellular source, 
function, and targets remain incompletely understood.31 However, a growing body of 
evidence points towards a role in early allergic but not late inflammatory processes, with 
remarkably transient IL-9 expression early after cellular activation.32-35 Therefore, IL-9 might 
be a model cytokine with a unique role in early transient immune activation but no 
importance for chronic inflammation. In accordance, the only clinical trial attempting at 
blocking IL-9 in human chronic asthma has failed to show efficacy.36 
 
In summary, the clinical efficacy of blocking distinct inflammatory signals in cutaneous 
disease with bimodal immune activation might not solely be determined by the involved 
pathways, but also by their ability to interfere with both the autoinflammatory and the 
autoimmune phase of skin inflammation. If this is the case, antagonism of early innate 
cytokines such as IL-1 might be more suitable to prevent new flares of psoriasis rather than 
to treat established plaques4 and inhibition of keratinocyte-derived signals like TSLP or IL-33 
might be more suitable to treat subclinical inflammation rather than established atopic 
dermatitis. Questions like these have so far not been addressed in clinical trials and remain 
to be elucidated by curious clinicians with both their patient’s wellbeing and pathomechanistic 
reflections in mind. 
 
Immune deviation instead of immune blockade? 
The simple concept of stopping inflammation by blocking or destroying immune signals could 
in the future be replaced by more elegant approaches. If we assume that inflammatory 
conditions arise due to misguided, normally beneficial signals, we could attempt to steer the 
immune metabolism back in its normal and healthy channels.  
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There are a series of remarkable studies along these lines that have all been performed 
more than 10 years ago.37-39 It appears that with the advent of monoclonal antibodies against 
cytokines, this idea has moved into the background, despite impressive clinical effects 
observed in these early studies. However, there are important lessons that likely can be 
learned from them that will also help understand and even predict clinical phenomena that 
arise or likely will arise in patients undergoing targeted therapy. On a very basic level, these 
studies have taught us that established inflammatory equilibria in skin lesions can be toppled 
by manipulating the pathways that stabilize them. For instance, treatment of psoriasis 
patients with recombinant IL-4 markedly improved psoriasis and induced pronounced 
skewing of intralesional cytokines towards a Th2 pattern while downregulating Th1/17 type 
inflammation.37 Recently, the mechanism of this interesting phenomenon that works by IL-4 
silencing IL-23 in antigen-presenting cells was demonstrated.40 Similar observations were 
made in psoriasis patients when treated with the anti-inflammatory cytokines IL-10 or IL-
11.38,39 Further investigation of the dynamics and half-life of these phenomena will yield 
interesting information about the stability of immune deviating strategies. This could answer 
whether we may ever be able to attempt a definite cure of psoriasis and other conditions with 
i.e. prolonged cytokine treatments or novel vaccinations that ideally would produce a long-
lasting effect.  
Pathologic immune deviation could also explain intriguing observations regularly made 
during clinical treatment of inflammatory dermatoses, such as sudden resistance to biologics 
without anti-drug antibodies, paradoxical psoriasis to TNF-α antagonists, and many more.  
Not addressed at all in clinical studies as yet was the question of spatially-localized immune 
cell swarms 41 in skin and the rest of the immune system. It is known for a while that skin-
resident T cells are stable and form a separate compartment from blood. Intriguing studies 
on co-existing atopic dermatitis and psoriasis in the same patients 42  demonstrated that even 
within skin, swarms of immune cells do not necessarily intermingle but can create a stable 
biological mosaic. These swarms may stem from pathologic immune deviation that could 
theoretically be addressed with cleverly topical treatments.  
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Finally, instead of a “horizontal” deviation such as from Th1/17 to Th2, one can also follow a 
strategy of immune activation to de-activation with IL-10 and TGF-β, or even the other way 
around such as is regularly done with success in oncology with CTLA4 and PD1 43,44 
antibodies.  
 
Multi-pronged intervention vs. monotherapy 
The current system of medical intervention with immunomodulating agents is primarily 
focused on the efficacy of single agents. This is easily understood when considering the 
complexity of performing studies with multiple compounds. However, in reality, the immune 
system is more complex and in most instances, more than one signal is involved in creating 
or sustaining pathology. Therefore, it might be beneficial and efficacious to inhibit more than 
one cytokine during treatment. Were such a strategy to be tested, it should first be shown 
that the target cytokines are indeed synergistic and not vertically arranged in a single 
pathway. Otherwise the inhibition of the upstream cytokine could already (theoretically) 
achieve the maximum efficacy on its own, eliminating the need to inhibit the downstream 
cytokine.  
Such synergistic combinations have already been analyzed in vitro, namely TNF-α and IL-17 
and IL-1 and IL-23 45,46. The cytokine combination was able to potentiate the result of the in 
vitro readout by several hundred-fold compared to what each single cytokine could achieve 
on its own - demonstrating the power of this strategy. It follows that also the success of 
cytokine inhibition could be improved dramatically by utilizing this effect. Very soon, such 
drugs will be in phase III clinical trials, including AbbVie’s ABT-122 bispecific antibody 
against IL-17 and TNF-α, Sanofi’s tetravalent bispecific tandem immunoglobulin (TBTI) 
against IL-4 and IL-13, and others. Such fixed combination drugs inhibiting two or more 
cytokines fit very well in our current system of clinical trials and registration, even though the 
information of contribution to the final effect may be lost.  
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In dermatology, we have the unique ability to combine systemic drugs with topical agents. So 
far, interesting questions such as to the effect of systemic TNF-antagonism together with 
local calcineurin-inhibition have not yet been addressed.  
 
Treatments based on Behemoth trials vs. Sherlockian approach 
Clinical medicine is both blessed and burdened with large randomized controlled trials (RCT) 
for virtually every important intervention. These large and hugely costly studies are currently 
considered a sine qua non for drug registration. Unfortunately, they also have many 
disadvantages that we cannot exhaustively enumerate here. Evidence hierarchies place RTC 
at the top, which however should not lead to a black-or-white worldview and discounting of all 
other, non-RCT evidence. We are all aware that for practical reasons only a part, possibly 
not even the majority of all diseases, can be studied by RCTs. Evidence on the rarer 
diseases or subtypes of common conditions, very young and old patients, ethnic minorities 
and the like tends to come from non-RCT studies including case reports. Although all such 
evidence needs to be interpreted cautiously, as a whole we believe it to be often very useful, 
at least for clinical decision-making in the same type of non-standardized situations that gave 
rise to the case reports. Table X includes a compilation of current evidence of case reports 
and clinical studies broken down according to dermatosis and treatment target. Outcomes of 
just one case or series are put in brackets. Collection of efficacy data of targeted treatments 
also reveals, perhaps most accurately of all approaches, the clinically relevant 
pathophysiology of each disease.  
Case reports have the obvious disadvantage of publication bias of positive results, non-
standardized treatment schemes and missing placebo controls. To overcome these 
limitations, N-of-1 strategies could be promoted to replace widespread off-label use in 
dermatology. These are proper small trials that closely observe the effect of an intervention 
in a single patient and can even be performed as a randomized controlled study by giving 
verum and placebo sequentially. Strategies for generic ethical approval of such interventions 
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could be generated, so that administrative constraints do not preclude clinicians from 
choosing this avenue of research. 
Taken together, we believe that decision making in common and well-studied situations such 
as moderate-to-severe plaque psoriasis should be based on RCT results and meta-analyses. 
In rarer, non-standard situations however, using evidence from case reports, especially with 
independently confirmed results, is acceptable as this is often the only available source of 
information. In our specialty with more than 2000 mostly rare conditions, case reports should 




The advent of targeted therapies for inflammatory skin disease has not only heralded an era 
where clinicians have manifold therapeutic options and patients benefit from unprecedented 
clinical efficacy, it has also opened new ways of investigating the pathogenesis underlying 
these complex skin conditions and of validating disease models that arise from basic 
research. Thanks to the well-defined molecular targets of these novel drugs, it is now 
possible to deduce pathomechanistic processes from clinical observations to an extent that 
has not been allowed by previous treatments with broad biological effects. In what can be 
called a “circle of induction and deduction” these insights continually feedback to and guide 
basic research which in turn results in the identification of novel drug targets that will 
eventually be tested in a clinical setting (Fig. X). As a consequence, we are today witnessing 
a translational revolution of model inflammatory skin diseases, most prominently of psoriasis 
and atopic dermatitis [Noda, 2015]. The future will certainly bring further innovation and, 
based on large trials and huge efforts from the industry, improved and precisely tailored 
treatments for these frequent diseases. However, targeted therapies also hold great promise 
for rare inflammatory skin diseases, where medical and scientific advance mainly relies on 
the initiative of curious clinicians and scientists. In this setting, it seems promising to harvest 
the scientific potential of assessing targeted therapies in small trials where translational 
analysis e.g. of sequental tissue samples before and under treatment are prone to yield a 
wealth of novel information on both disease mechansisms and mode of action of the 
investigated drug. Successful examples of such translational approaches are continuously 
published from all fields of dermatology and are likely to further shape the way we 
understand our patients and their treatments in the future [Clark RA, Sci Transl Med, 2012, 
etc]. 
As the field of translational medicine continues to evolve and the number of available 
targeted therapies increases we will undoubtedly see further refinements of current disease 
models. The concept of bimodal immune activation postulating that early inflammatory 
events are distinct from, but intimately linked to, later chronic inflammation has the potential 
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to introduce different treatment modalities for patients with acute or chronic disease and to 
promt the development of relapse-preventing therapeutics [Christophers, BJD]. Animal 
models used in basic research can be validated by careful comparison with clinical studies of 
targeted therapies, thus assessing strengths and weaknesses of the respective models. 
Combined inhibition of targets with synergistic pathogenic potential will likely add a highly 
effective treatment options for patients with recalcitrant disease. 
In summary, targeted therapies have profoundly influenced not only the treatment but also 
the understanding of psoriasis and are likely to have a similar impact on other model 
inflammatory skin diseases such as atopic dermatitis. Further translational research in this 
field holds the promise that similar developments will also take place in less common 
inflammatory skin diseases, making the impressive therapeutic potential of targeted drugs 
available to many more patients while teaching their doctors valuable lessons about the 
underlying disease.    
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